# US 2024/0200071 A1 · Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200071 A1
- Document ID: US20240200071A1
- Status: Published application
- Kind: A1
- Application number: 18/527,920
- Filed: 2023-12-04
- Published: 2024-06-20
- Earliest claimed: 2017-11-13
- Assignees: Silence Therapeutics GmbH
- Applicants: Silence Therapeutics GMBH
- Inventors: Lucas Bethge; Judith Hauptmann; Christian Frauendorf; Adrien Weingärtner
- Web page: https://patentgrep.com/patent/US20240200071A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/351: Conjugate
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/30: chemically synthesised
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.

## Claims

### Claim 1

A method of preventing or treating a disease, disorder or syndrome, the method comprising administering to a subject a composition comprising a nucleic acid for inhibiting expression of a target gene in a cell, comprising at least one duplex region that comprises at least a portion of a first strand and at least a portion of a second strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene, wherein said first and/or second strand comprises a phosphorodithioate linkage between at least two nucleotides.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first strand does not comprise a phosphorodithioate linkage between any of the two, three or four terminal nucleotides at the 5′ end.

### Claim 3 (depends on 1)

The method of claim 1, wherein the nucleic acid comprises a phosphorodithioate linkage between either the two, three or four terminal nucleotides at the 3′ end of the first strand; and/or comprises a phosphorodithioate linkage between either the two, three or four terminal nucleotides at the 3′ end of the second strand; and/or a comprises a phosphorodithioate linkage between either the two, three or four terminal nucleotides at the 5′ end of the second strand.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nucleic acid comprises a phosphorothioate linkage between each of the three terminal 3′ nucleotides and/or between each of the three terminal 5′ nucleotides on the first strand, and/or between each of the terminal three 3′ nucleotides and/or between each of the terminal three 5′ nucleotides of the second strand when there is no phosphorodithioate linkage present at that end.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first strand and the second strand are separate strands.

### Claim 6 (depends on 1)

The method of claim 1, wherein the at least one duplex region consists of 17-25 nucleotide base pairs.

### Claim 7 (depends on 1)

The method of claim 1, wherein one or more nucleotides on the first and/or second strand are modified.

### Claim 8 (depends on 1)

The method of claim 1, wherein the nucleic acid is conjugated to a ligand.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ligand comprises (i) one or more N-acetyl galactosamine (GalNAc) moieties or derivatives thereof, and (ii) a linker, wherein the linker conjugates the at least one GalNAc moiety or derivative thereof to the nucleic acid.

### Claim 10 (depends on 1, 8)

The method of claim 8, wherein the nucleic acid is conjugated to a ligand comprising a compound of formula (I):
[S—X1—P—X2]3-A-X3— (1)
wherein:
S represents a saccharide;
X1 represents C3-C6 alkylene or (—CH2—CH2—O)m(—CH2)2— wherein m is 1, 2, or 3;
P is a phosphate or modified phosphate;
X2 is alkylene or an alkylene ether of the formula (—CH2)n—O—CH2— where n=1-6;
A is a branching unit;
X3 represents a bridging unit;
wherein a nucleic acid as defined in claim 1 is conjugated to X3 via a phosphate or modified phosphate.

### Claim 11 (depends on 8)

The method of claim 8, wherein the first RNA strand is a compound of formula (X):
wherein b is 0 or 1; and
the second RNA strand is a compound of formula (XI):
wherein:
c and d are independently 0 or 1;
Z1 and Z2 are the RNA portions of the first and second RNA strands respectively;
Y is O or S;
n is 0, 1, 2 or 3; and
L1 is a linker to which a ligand is attached; and
wherein b+c+d is 2 or 3.

### Claim 12

A method of preventing or treating a disease, disorder or syndrome, the method comprising administering to a subject a composition comprising a nucleic acid, comprising at least one duplex region that comprises at least a portion of a first strand and at least a portion of a second strand that is at least partially complementary to the first strand, wherein said first strand is at least partially complementary to at least a portion of RNA transcribed from said target gene,
wherein the nucleic acid comprises phosphorodithioate linkages between the two terminal nucleotides at the 3′ end of the first strand, and
between the two terminal nucleotides at the 3′ end and the two terminal nucleotides at the 5′ end of the second strand; and
wherein the first strand comprise a linkage other than a phosphorodithioate between the two, three or four terminal nucleotides at the 5′ end.

### Claim 13 (depends on 12)

The method of claim 12, wherein
the nucleic acid is conjugated to a ligand comprising a compound of formula (I):
[S—X1—P—X2]3-A-X3— (1)
wherein:
S represents a saccharide;
X1 represents C3-C6 alkylene or (—CH2—CH2—O)m(—CH2)2— wherein m is 1, 2, or 3;
P is a phosphate or modified phosphate;
X2 is alkylene or an alkylene ether of the formula (—CH2)n—O—CH2— where n=1-6;
A is a branching unit;
X3 represents a bridging unit;
wherein a nucleic acid as defined in claim 12 is conjugated to X3 via a phosphate or modified phosphate.

### Claim 14 (depends on 12)

The method of claim 12, wherein the nucleic acid is conjugated to a ligand, wherein the first RNA strand is a compound of formula (XV):
wherein b is 0 or 1; and
the second RNA strand is a compound of formula (XVI):
wherein c and d are independently 0 or 1;
wherein:
Z1 and Z2 are the RNA portions of the first and second RNA strands respectively;
Y is O or S;
R1 is H or methyl;
n is 0, 1, 2 or 3; and
L is the same or different in formulae (XV) and (XVI) and is selected from the group consisting of:
—(CH2)q, wherein q=2-12;
—(CH2)r—C(O)—, wherein r=2-12;
—(CH2—CH2—O)s-CH2—C(O)—, wherein s=1-5;
—(CH2)t—CO—NH—(CH2)t—NH—C(O)—, wherein t is independently is 1-5;
—(CH2)u—CO—NH—(CH2)u—C(O)—, wherein u is independently is 1-5; and
—(CH2)v—NH—C(O)—, wherein v is 2-12; and
wherein the terminal C(O), if present, is attached to the NH group;
and wherein b+c+d is 2 or 3.

### Claim 15 (depends on 12)

The method of claim 12, wherein the first RNA strand has a terminal 5′ (E)-vinylphosphonate nucleotide at its 5′ end.

### Claim 16 (depends on 12)

The method of claim 12, wherein the nucleotides of the first strand are modified by a first modification on the odd numbered nucleotides, and modified with a second modification on the even numbered nucleotides, and wherein the nucleotides of the second strand are modified on the odd numbered nucleotides with the second modification and modified with the first modification on the even numbered nucleotides, wherein the first strand is numbered 5′ to 3′, the 5′-most nucleotide being nucleotide number 1 of the first strand and the second strand is numbered 3′ to 5′, the 3′-most nucleotide being nucleotide number 1 of the second strand.

### Claim 17 (depends on 12)

The method of claim 12, wherein the nucleotides at positions 2 and 14 from the 5′ end of the first strand are modified with a 2′ fluoro modification, and the nucleotides on the second strand which correspond to position 11, or 13, or 11 and 13, or 11-13 of the first strand are modified with a 2′ fluoro modification.

### Claim 18 (depends on 12)

The method of claim 12, wherein all the linkages between the nucleotides of both strands other than the linkage between the two terminal nucleotides at the 3′ end of the first strand and the linkages between the two terminal nucleotides at the 3′ end and the 5′ end of the second strand, are unsubstituted phosphate linkages.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the nucleic acid or composition is administered to the subject subcutaneously, intravenously, orally, rectally or intraperitoneally.

### Claim 23 (depends on 12)

The method of claim 12, wherein the nucleic acid is administered to the individual subcutaneously, intravenously, orally, rectally or intraperitoneally.

### Claim 24 (depends on 10)

The method of claim 10, wherein the saccharide is N-acetyl galactosamine.

### Claim 25 (depends on 13)

The method of claim 13, wherein the saccharide is N-acetyl galactosamine.

### Claim 26 (depends on 15)

The method of claim 15, wherein the terminal 5′ (E)-vinylphosphonate nucleotide is linked to the second nucleotide in the first strand by a phosphodiester linkage.

### Claim 27 (depends on 16)

The method of claim 16, wherein the first modification is 2′OMe.

### Claim 28 (depends on 16)

The method of claim 16, wherein the second modification is 2′ fluoro.

### Claim 29 (depends on 16)

The method of claim 16, wherein the nucleic acid is blunt ended at both ends.

### Claim 30 (depends on 17)

The method of claim 17, wherein the remaining nucleotides are modified with a 2′OMe modification.
